Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
NCT03618550Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in Hodgkin lymphoma (HL) (6 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Complete Response Rate at 2 years and Freedom From Disease at 5 years. Started Aug 2018; status: recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03618550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618550.